1. Patient-Focused Drug Development. (2018). Guidance 3 discussion document: Select, develop or modify fit-for-purpose clinical outcomes assessments. Retrieved March 26, 2021, from https://www.fda.gov/media/116277/download
2. Deyo, R. A., & Inui, T. S. (1984). Toward clinical applications of health status measures: Sensitivity of scales to clinically important changes. Health Services Research, 19(3), 275–289.
3. Jaeschke, R., Singer, J., & Guyatt, G. H. (1989). Measurement of health status. Ascertaining the minimal clinically important difference. Controlled Clinical Trials, 10(4), 407–415. https://doi.org/10.1016/0197-2456(89)90005-6
4. U.S. FDA. (2009). US department of health and human services food and drug administration guidance for industry: Patient-reported outcome measures: Use in medical product development to support labeling claims. Retrieved March 26, 2021, from https://www.fda.gov/media/77832/download
5. Patient-Focused Drug Development. (2019). Guidance 4 discussion document: Incorporating clinical outcome assessments into endpoints for regulatory decision making. Retrieved March 26, 2021, from https://www.fda.gov/media/132505/download